UK Markets close in 8 hrs 9 mins
  • FTSE 100

    5,801.81
    -58.47 (-1.00%)
     
  • FTSE 250

    17,914.69
    -194.88 (-1.08%)
     
  • AIM

    977.83
    -2.62 (-0.27%)
     
  • GBP/EUR

    1.1002
    +0.0011 (+0.10%)
     
  • GBP/USD

    1.3009
    -0.0029 (-0.2225%)
     
  • BTC-GBP

    10,019.85
    +1.42 (+0.01%)
     
  • CMC Crypto 200

    261.90
    +0.44 (+0.17%)
     
  • S&P 500

    3,465.39
    +11.90 (+0.34%)
     
  • DOW

    28,335.57
    -28.13 (-0.10%)
     
  • CRUDE OIL

    38.49
    -1.36 (-3.41%)
     
  • GOLD FUTURES

    1,903.30
    -1.90 (-0.10%)
     
  • NIKKEI 225

    23,494.34
    -22.25 (-0.09%)
     
  • HANG SENG

    24,918.78
    +132.68 (+0.54%)
     
  • DAX

    12,297.25
    -348.50 (-2.76%)
     
  • CAC 40

    4,840.06
    -69.58 (-1.42%)
     

argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020

argenx SE
·2-min read


October 15, 2020

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2020 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its third quarter 2020 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.

Dial-in numbers:
Please dial in 15 minutes prior to the live call.

Belgium 0800 389 13
France 0805 102 319
Netherlands 0800 949 4506
United Kingdom 0800 279 9489
United States 1 866 270 1533
International 1 412 317 0797

About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan. For more information, visit www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/.

For further information, please contact:

Beth DelGiacco, Vice President, Investor Relations (US)
+1 518 424 4980
bdelgiacco@argenx.com

Joke Comijn, Director Corporate Communications & Investor Relations (EU)
+32 (0)477 77 29 44
+32 (0)9 310 34 19
jcomijn@argenx.com